Despite the two controlled trials enrolled only patients with IgM MGUS (being WM an exclusion criterion), patients with anti-MAG antibody neuropathy and WM display a similar response to rituximab, with a more persistent benefit in patients with short disease duration [70]. Here, CD40LG is linked to neuropathy.